IN2012DN00765A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00765A
IN2012DN00765A IN765DEN2012A IN2012DN00765A IN 2012DN00765 A IN2012DN00765 A IN 2012DN00765A IN 765DEN2012 A IN765DEN2012 A IN 765DEN2012A IN 2012DN00765 A IN2012DN00765 A IN 2012DN00765A
Authority
IN
India
Prior art keywords
medicament
compound
formula
well
pharmaceutically acceptable
Prior art date
Application number
Inventor
Li Chen
Lichun Feng
Mengwei Huang
Jia Li
Fajun Nan
Tao Pang
Lifang Yu
Mei Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN00765A publication Critical patent/IN2012DN00765A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R7 have the significance given in claim 1, can be used as a medicament.
IN765DEN2012 2009-09-21 2010-09-20 IN2012DN00765A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2009/074060 WO2011032320A1 (en) 2009-09-21 2009-09-21 Novel alkene oxindole derivatives
PCT/EP2010/063770 WO2011033099A1 (en) 2009-09-21 2010-09-20 Alkene oxindole derivatives and their uses to treat obesity, diabetes and hyperlipidemia

Publications (1)

Publication Number Publication Date
IN2012DN00765A true IN2012DN00765A (en) 2015-06-26

Family

ID=43414813

Family Applications (1)

Application Number Title Priority Date Filing Date
IN765DEN2012 IN2012DN00765A (en) 2009-09-21 2010-09-20

Country Status (10)

Country Link
US (3) US20110071195A1 (en)
EP (1) EP2480530A1 (en)
JP (1) JP2013505281A (en)
KR (1) KR20120068876A (en)
AU (1) AU2010297252A1 (en)
BR (1) BR112012006172A2 (en)
CA (1) CA2772674A1 (en)
IN (1) IN2012DN00765A (en)
MX (1) MX2012002477A (en)
WO (2) WO2011032320A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
US20150005353A1 (en) * 2012-02-10 2015-01-01 Virginia Commonwealth University 3-(2-amino-ethyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-alkylidene-1,3-dihydro-indol-2-one derivatives as selective sphingosine kinase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2769974A1 (en) * 2013-02-21 2014-08-27 Debiopharm S.A. Novel AMPK activator
JP6064062B2 (en) 2013-03-15 2017-01-18 ファイザー・インク Indazole compounds that activate AMPK
WO2014202528A1 (en) * 2013-06-20 2014-12-24 Boehringer Ingelheim International Gmbh Olefin substituted oxindoles having ampk activity
EP2886541A1 (en) * 2013-12-19 2015-06-24 Sanofi Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases
ES2567105B1 (en) * 2014-09-19 2017-02-10 Consejo Superior De Investigaciones Científicas (Csic) INDOL DERIVATIVES FOR THE PREVENTION AND / OR TREATMENT OF RELATED METABOLIC DIABETES AND DISORDERS
CN106619616A (en) * 2015-11-04 2017-05-10 中国科学院上海药物研究所 Application of 3-alkenyl indolone derivatives to preparing medicines for treating MIRI (myocardial ischemia-reperfusion injury) and medicine composition with 3-alkenyl indolone derivatives
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
JP2024540522A (en) 2021-11-19 2024-10-31 ザ・ブロード・インスティテュート・インコーポレイテッド Bifunctional chimeric molecules for labeling kinases with target binding moieties and methods of use thereof - Patents.com

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243034T1 (en) * 1996-01-17 2003-07-15 Taiho Pharmaceutical Co Ltd INTIMAL THICKENING INHIBITORS
EP0984930B1 (en) * 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
DE19816624A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JPWO2007032371A1 (en) * 2005-09-14 2009-03-19 大日本住友製薬株式会社 Oxindole derivatives as feeding regulators
KR101507375B1 (en) * 2006-09-15 2015-04-07 엑스커버리 홀딩 컴퍼니 엘엘씨 Kinase inhibitor compounds
CA2707047C (en) * 2007-12-12 2017-11-28 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
MX2010008376A (en) * 2008-02-04 2011-02-22 Mercury Therapeutics Inc Ampk modulators.
JP5557845B2 (en) * 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション Novel cyclic benzimidazole derivatives useful as antidiabetic agents
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives

Also Published As

Publication number Publication date
MX2012002477A (en) 2012-03-26
KR20120068876A (en) 2012-06-27
WO2011033099A1 (en) 2011-03-24
US8778973B2 (en) 2014-07-15
JP2013505281A (en) 2013-02-14
WO2011032320A1 (en) 2011-03-24
EP2480530A1 (en) 2012-08-01
CA2772674A1 (en) 2011-03-24
AU2010297252A1 (en) 2012-02-02
US20110071195A1 (en) 2011-03-24
US20140288127A1 (en) 2014-09-25
BR112012006172A2 (en) 2016-05-31
US20130131114A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
IN2012DN00765A (en)
IN2012DN03337A (en)
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
MX2011012739A (en) Fluorinated aminotriazole derivatives.
MX2022007264A (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof.
MY184306A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
PH12013500942A1 (en) Triazolopyridine compounds
MY153985A (en) Aminotriazole derivatives as alx agonists
MX2011011094A (en) Proline derivatives as cathepsin inhibitors.
ZA201002987B (en) Tropane compounds
PH12014500813A1 (en) Novel [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor
MY183312A (en) Pharmaceutical formulation
IN2012DN03182A (en)
NZ595705A (en) Protease inhibitors
PH12015502429A1 (en) Dicarboxylic acid compound
MX2014004920A (en) Novel pyrazine derivatives.
IN2012DN01232A (en)
MX2015015755A (en) Perhydroquinoxaline derivatives useful as analgesics.
JO2781B1 (en) New Process For The Synthesis Of Ivabradine And Addition Salts Thereof With A Pharmaceutically Acceptable Acid
MX2011011716A (en) Novel isoquinoline derivatives.
MX2014008918A (en) Novel pyrrolidine derivatives.
MX2013008256A (en) Novel tetrahydroquinoline derivatives.
MX346090B (en) Pyrrolidine derivatives used as cathepsin inhibitors.
MX2013002694A (en) Tetrahydroquinoline derivatives used as ampk activators.
JO2782B1 (en) New Process For The Synthesis Of Ivabradine And Addition Salts Thereof With A Pharmaceutically Acceptable Acid